The US FDA and EMA currently approved various nanotechnology-based anticancer drugs, such as Myocet (Teva UK) (EMA 2000) (liposomal doxorubicin (non-PEGylated)) (treatment of metastatic breast cancer), DaunoXome (Galen) (FDA 1996, EMA 2018) (liposomal daunorubicin (non-PEGylated)) (HIV-associated Kaposi’s sarcoma), ONPATTRO Patisiran ALN-TTR02 (Alnylam Pharmaceuticals) (FDA 2018) (lipid nanoparticle RNAi) (Transthyretin (TTR)-mediated amyloidosis), and VYXEOS CPX-351 (Jazz Pharmaceuticals) (FDA 2017, EMA 2018) (liposomal formulation of cytarabine: daunorubicin) (acute myeloid leukaemia) [21]. This evidence concerns the gene TTR and amyloidosis.